Evaluation of the Post-COVID-19 Functional Status (PCFS) Scale in a cohort of patients recovering from hypoxemic SARS-CoV-2 pneumonia. Issue 1 (9th March 2022)

• Record Type: Journal Article
• Authors: Benkalfate, Naïla; Eschapasse, Emmanuel; Georges, Thomas; Leblanc, Camille; Dirou, Stephanie; Melscoet, Lise; Chéné, Anne-Laure; Horeau-Langlard, Delphine; Bry, Charlotte; Chambellan, Arnaud; Nicolas, Aymeric; Claire, Defrance; Liberge, Renan; Karakachoff, Matilde; Hardouin, Jean-Benoit; Blanc, François-Xavier; Lemarchand, Patricia
• Is Part Of: BMJ open respiratory research. Volume 9:Issue 1(2022)
• Publication Date: 2022-03-09
• Subjects: COVID-19 -- viral infection -- respiratory infection -- pneumonia; Respiratory organs -- Diseases -- Periodicals; Respiratory organs -- Diseases -- Treatment -- Periodicals; Respiratory therapy -- Periodicals; 616.2005
• DOI: 10.1136/bmjresp-2021-001136
• Languages: English
• ISSNs: 2052-4439

Abstract

Abstract : Introduction: COVID-19 sequelae are numerous and multisystemic, and how to evaluate those symptomatic patients is a timely issue. Klok et al proposed the Post-COVID-19 Functional Status (PCFS) Scale as an easy tool to evaluate limitations related to persistent symptoms. Our aim was to analyse PCFS Scale ability to detect functional limitations and its correlation with quality of life in a cohort of patients, 2–9 months after hospitalisation for COVID-19 hypoxemic pneumonia. Methods: PCFS Scale was evaluated in 121 patients together with quality of life and dyspnoea questionnaires, pulmonary function tests and CT scans. Results: We observed a high correlation with multiple questionnaires (Short Form-36, Hospital Anxiety and Depression Scale, modified Medical Research Council, end Borg Six-Minute Walk Test), making the PCFS Scale a quick and global tool to evaluate functional limitations related to various persistent symptoms following COVID-19 pneumonia. Discussion: The PCFS Scale seems to be a suitable instrument to screen for patients who will require careful follow-up after COVID-19 hypoxemic pneumonia even in the absence of pulmonary sequelae.